

**Andrew E. Jaffe, Ph.D.**  
[andrew.e.jaffe@gmail.com](mailto:andrew.e.jaffe@gmail.com)  
<https://aejaffe.com/>

**Executive Summary:** As a seasoned executive leader with a proven track record building and leading cross-functional data science, machine learning, and computational biology teams, I have the unique ability to translate between data sciences, life sciences and clinical sciences to maximize impact to drug programs. I have over 15 years of experience in data science, machine learning, human genetics, and bioinformatics, and leveraging large-scale data analytics across entire pipelines, from early discovery to late-stage clinical development. I have built and led high performing teams in multiple organizations which combined cutting edge data, life and clinical sciences to create pipeline/portfolio impact and value.

**Current position(s):**

*(1) Vice President, Head of Data Sciences, Neumora Therapeutics [Sept 2020- June 2026]*

- Extensive involvement in clinical development across our entire portfolio, spanning early drug development (lead series) to Phase 3 across neuropsychiatric and neurodegenerative disorders; co-inventor on several use patents related to navacaprant, a kappa opioid receptor antagonist, in depression [WO2024216061A1] and anhedonia [WO2024216046A1]
- Led a cross-functional team of data and machine learning scientists developing cutting-edge computational solutions across the entire drug discovery and development pipeline. We work closely with R&D colleagues across target discovery, target validation, phase-specific clinical development, biometrics/biostatistics and clinical operations to identify business problems, translate these into computational code/software and discover business insights.
- Led machine learning groups inventing novel statistical and machine learning frameworks for optimizing clinical trials and their execution using supervised (e.g. placebo/treatment response modeling) and unsupervised (e.g. uni- and multi-modal patient clustering) approaches, resulting in valuable patents for our company [US20240021298A1, US20230107415A1]
- Developed fit-for-purpose development strategies to enhance drug response and reduce placebo response using wide array of data modalities, including genetic variation, gene expression, proteomics, electroencephalogram (EEG), [functional] magnetic resonance imaging ([f]MRI), digital instrumentation, and clinical symptomatology.
- Senior-level engagement: briefed the executive committee, engaged our Board of Directors, participated in investor pitches for our Series A fundraising, and led strategic partnerships
- Team building at the intersection of life sciences and data sciences - recruiting/retaining, coaching/mentoring, creating a high performance and high trust culture, building bridges

across all functions of the company, forming external partnerships, and integrating this all together to enable success of the team and its impact on the overall company.

*(2) Associate Professor (Adjunct), Department of Psychiatry and Behavioral Sciences and Department of Neuroscience; Johns Hopkins School of Medicine; Baltimore, MD*

#### **Past Positions:**

*(3) Group Leader, Data Science & Lead Investigator, Translational Sciences Division: Lieber Institute for Brain Development [April 2013- Sept 2020]*

- Leveraged human postmortem brain tissue and cellular models to identify molecular mechanisms and signatures related to the causes and consequences of severe mental illness across my own federally-funded projects, institute-wide initiatives like pharma-sponsored research agreements, and collaboration with molecular scientists.
- Extensive track record acquiring federal NIH funding, with leading Principal Investigator (PI) role (including multiple PI, MPI) on 10 funded NIH grants (5 R01s, 1 U01, 4 R21s) for >\$20M in total costs, and co-investigator on another 8 NIH research grants. This funded organic lab growth from a single research assistant to > 10 PhD students, research assistants and staff scientists.
- Wide-ranging track record publishing research articles, with >145 across my academic career. I have an H-index of 65 (via [Google Scholar](#)) and was a “[Highly Cited Researcher](#)” for top 1% of research in 2018.
- Broad experience in [bulk](#), [single cell/nucleus](#) and [spatial transcriptomic](#) RNA sequencing technologies across data generation, analysis, interpretation, and translation
- Developed new computational and laboratory approaches for [processing](#), [normalizing](#) and [analyzing](#) epigenomic and transcriptomic data to enhance wanted biological signal while minimizing technical and unwanted biological signal.

*(4) Associate Professor (Primary), Department of Mental Health; Johns Hopkins Bloomberg School of Public Health; Baltimore, MD. Secondary: Biostatistics and Human Genetics.*

#### **Education:**

- 12/2011: PhD in Epidemiology (Human Genetics/Genetic Epidemiology), Johns Hopkins Bloomberg School of Public Health, Department of Epidemiology
  - Thesis: Incorporating High-Throughput DNA Methylation Data in Epidemiological Studies
- 12/2011: MHS in Bioinformatics, Johns Hopkins Bloomberg School of Public Health, Department of Biostatistics and Department of Molecular Microbiology and Immunology